Sedia Biosciences Corporation develops HIV incidence assays, which are epidemiological tools for fighting the HIV epidemic. These products represent a laboratory assay-based approach for conducting HIV-1 surveillance, enabling the estimation of HIV-1 incidence rates. Unlike "prevalence" which is a measure of the number of infected individuals per given number of persons (i.e. a population), "Incidence" is the number of new infections per given number of persons (i.e. population) over a period of time. Classical diagnostic tests which indicate whether or not an individual is infected, can determine prevalence, but not incidence, since they do not determine if the infected individual was infected recently (i.e. a "new" infection) or was infected a long time ago (a "long-term" infection). Sedia is now adapting its platform to a variety of other infectious disease analytes, e.g. Hepatitis B SAg, Hepatitis C Ab, syphilis, etc.
